Ontology highlight
ABSTRACT:
SUBMITTER: Gu S
PROVIDER: S-EPMC4924747 | biostudies-literature | 2016 Mar
REPOSITORIES: biostudies-literature
Gu Shenda S Hu Zhi Z Ngamcherdtrakul Worapol W Castro David J DJ Morry Jingga J Reda Moataz M MM Gray Joe W JW Yantasee Wassana W
Oncotarget 20160301 12
HER2 is overexpressed in about 20% of breast cancers and contributes to poor prognosis. Unfortunately, a large fraction of patients have primary or acquired resistance to the HER2-targeted therapy trastuzumab, thus a multi-drug combination is utilized in the clinic, putting significant burden on patients. We systematically identified an optimal HER2 siRNA from 76 potential sequences and demonstrated its utility in overcoming intrinsic and acquired resistance to trastuzumab and lapatinib in 18 HE ...[more]